About Us

A recent surge in new technologies spanning protein detection and analysis of minute amounts of DNA, RNA and proteins, and the application of artificial intelligence (AI) in all aspects of medicine will help us identify cancer at the earliest stages of development in order to intervene sooner. As has repeatedly been demonstrated, detecting and treating cancer earlier leads to better outcomes, increasing both survival rates and quality of life.

Currently, the standard of care in screening for cancer is limited to a handful of malignancies, each requiring their own procedures such as colonoscopies, which are invasive, costly and time consuming. The possibility of using a single blood sample to screen for multiple cancers, so called ‘multi-cancer early detection (MCED) tests’, would be transformational for care. MCEDs provide a unique opportunity to make health care more equitable and rewrite the current standard of care guidelines but there are considerable barriers to full implementation of such tests.

In this rapidly changing landscape, CEDI is a coordinated effort to determine precisely when and how early detection leads to faster treatment and improves outcomes. CEDI clinician-scientists will develop rational, cost-effective, and equitable approaches to improve early detection through the application of known and AI-informed risk assessments, bioassays, and state-of-the-art imaging. They will analyze existing early detection technology to inform future strategy and implement the infrastructure needed to provide clinical diagnostic care equitably and connect each individual with the appropriate expert, treatment plan, and/or clinical trial.